Publications by authors named "Teodora Festini"
Article Synopsis
- - SDZ-ADL (GP2017) is a biosimilar to adalimumab that was studied in two phase III trials focusing on its impact on quality of life and patient-reported outcomes in chronic plaque psoriasis and rheumatoid arthritis.
- - Both studies confirmed that SDZ-ADL had similar efficacy, safety, and immunogenicity compared to the reference drug, with patients experiencing comparable improvements in quality of life metrics like the Dermatology Life Quality Index and EuroQol health status.
- - Results showed significant reductions in quality of life impact from baseline scores in both treatment groups, and improvements were maintained even after treatment switches over the study period.
The subcutaneous administration route is widely used to administer different types of drugs given its high bioavailability and rapid onset of action. However, the sensation of pain at the injection site might reduce patient adherence. Apart from a direct effect of the drug itself, several factors can influence the sensation of pain: needle features, injection site, volume injected, injection speed, osmolality, viscosity and pH of formulation, as well as the kind of excipients employed, including buffers and preservatives.
View Article and Find Full Text PDF